Naos fund reaps life science and biotech rewards
Wed Apr 18, 2012
Investments in Australian biotech and life sciences
companies helped lift the Naos Emerging Long Short Equity Fund
in March. The fund, which focuses exclusively on Australian
equities, rose 9.33% in March, after a 11.83% gain in
ISSN: 2151-1845 / CDC10004H
The full contents of this article are available to active AsiaHedge subscribers and trialists only.
TAKE A FREE TRIAL
To continue reading please, take a free trial or subscribe to AsiaHedge.
Subscribers have unlimited access to all current content, including hedge fund performance Live League Tables. Start your subscription today - click on the button below.